

**Attendance certificate**

2024-05-27

ATTESTERAD 2024-05-27

To whom it may concern:

This is to certify that Dara Mohammad has actively attended in the following Cell and Gene Therapy Group seminars.  
He has also presented twice in Fall 2023 and Spring 2024.

| No. | Date           | Time        | Meeting          | 20 min Presentation        | Title of Presentation   |
|-----|----------------|-------------|------------------|----------------------------|---|
| 1   | Aug 31, 2023   | 13:00-14:30 | EA group meeting | <b>Alamdar Hussain</b>     | Modulators of the Immune Escape Mechanism for Universal Cell Therapy                                |
| 2   | Sept 07, 2023  | 13:00-14:30 | EA group meeting | <b>Anna Pumpa</b>          | GEAR project-Generation of CD38 KO primary NK cells using electroporation of CRISPR/Cas9 components |
| 3   | Sept 21, 2023  | 13:00-14:30 | EA group meeting | <b>Hazel Reilly</b>        | Synergies in NK cell receptors  |
| 4   | Oct 05, 2023   | 13:00-14:30 | EA group meeting | <b>Dara Mohammad</b>       | Engineering NK cells to target Multiple Myeloma cells   |
| 5   | Oct 19, 2023   | 13:00-14:30 | EA group meeting | <b>Stephan Meinke</b>      | Pre-clinical evaluation of anti-ROR1 CAR  |
| 6   | Nov 02, 2023   | 13:00-14:30 | EA group meeting | <b>Quirin Hammer</b>       | How can the rejection of adoptively transferred cells be reduced                                    |
| 7   | Nov 09, 2023   | 13:00-14:30 | EA group meeting | <b>Katharina Susek</b>     | Strategies to optimize natural killer cell functions in the tumor microenvironment                  |
| 8   | Nov 16, 2023   | 13:00-14:30 | EA group meeting | <b>Sophia Borate</b>       | Reprogramming strategies to generate iPSC by expression of Yamanaka factors                         |
| 9   | Nov 30, 2023   | 13:00-14:30 | EA group meeting | <b>Nutsa Burduli</b>       | CRISPR screening of human NK cells to identify NK cytotoxic drivers                                 |
| 10  | Dec 07, 2023   | 13:00-14:30 | EA group meeting | <b>Muhammad K</b>          | creating an <i>in vitro</i> model for treatment resistance in MM patients harbouring t(11;14)       |
| 11  | Dec 14, 2023   | 13:00-14:30 | EA group meeting | <b>Juliette Suermondt</b>  | Role of BiTE/BiKE in NK/T cell cancer immunotherapy   |
| 12  | Jan 25, 2024   | 13:00-14:30 | EA group meeting | <b>Qindong Zhang</b>       | Development of Macrophage-based Therapies against Tumors. Her project was                           |
| 13  | Feb 01, 2024   | 13:00-14:30 | EA group meeting | <b>Terumo presentation</b> | Quantum Flex System: Where Cells Thrive   |
| 14  | Feb 15, 2024   | 13:00-14:30 | EA group meeting | <b>Alamdar Hussain</b>     | NRG1 platform for GAGE models   |
| 15  | Feb 22, 2024   | 13:00-14:30 | EA group meeting | <b>Anna Pumpa</b>          | Strategies to engineer NK cells to improve immunotherapy  |
| 16  | Feb 29, 2024   | 13:00-14:30 | EA group meeting | <b>Hazel Reilly</b>        | VyOz toxicity in iPSCs and transgene silencing in iPSCs   |
| 17  | Mar 07, 2024   | 13:00-14:30 | EA group meeting | <b>Dara Mohammad</b>       | Redirect NK cells employing TIGIT-based chimeric switch receptor for Cancer immunotherapy           |
| 18  | Mar 14, 2024   | 13:00-14:30 | EA group meeting | <b>Quirin Hammer</b>       | Plaucity of peptide presentation as viral escape from NK cell recognition                           |
| 19  | Mar 21, 2024   | 13:00-14:30 | EA group meeting | <b>Sophia Borate</b>       | VyM Myc mRNA for expansion of PBMCs   |
| 20  | April 4, 2024  | 13:00-14:30 | EA group meeting | <b>Juliette Suermondt</b>  | SynNotch EVs projec   |
| 21  | April 11, 2024 | 13:00-14:30 | EA group meeting | <b>Nutsa Burduli</b>       | Antibodies targeting DNAM-1 and TIGIT   |
| 22  | May 2, 2024    | 13:00-14:30 | EA group meeting | <b>Muhammad K</b>          | Prognostic and prediction of short-term survival of MM patients.                                    |

Yours sincerely,



Evren Alici  
MD, PhD, Associate professor (Group Leader)  
Karolinska Institutet  
Department of Medicine Huddinge  
SE 141 83 Stockholm, Sweden  
E-mail: evren.alici@ki.se  
Telephone: +46-8-585 83646

ATTESTERAD 2024-05-27